Literature DB >> 24999930

First QIDP drug approved, but designation may fail urgent needs.

Amanda B Keener.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24999930     DOI： 10.1038/nm0714-690

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  3 in total

1.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; Daniel K Benjamin; John Bradley; Robert J Guidos; Ronald N Jones; Barbara E Murray; Robert A Bonomo; David Gilbert
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

2.  Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Authors:  Helen W Boucher; Mark Wilcox; George H Talbot; Sailaja Puttagunta; Anita F Das; Michael W Dunne
Journal:  N Engl J Med       Date:  2014-06-05       Impact factor: 91.245

3.  Single-dose oritavancin in the treatment of acute bacterial skin infections.

Authors:  G Ralph Corey; Heidi Kabler; Purvi Mehra; Sandeep Gupta; J Scott Overcash; Ashwin Porwal; Philip Giordano; Christopher Lucasti; Antonio Perez; Samantha Good; Hai Jiang; Greg Moeck; William O'Riordan
Journal:  N Engl J Med       Date:  2014-06-05       Impact factor: 91.245
  3 in total
  2 in total

1.  Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.

Authors:  Esther Bettiol; Jeffrey D Wetherington; Nicola Schmitt; Stephan Harbarth
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

Review 2.  Trends in therapeutic drug conjugates for bacterial diseases: a patent review.

Authors:  Pedro M S D Cal; Maria J Matos; Gonçalo J L Bernardes
Journal:  Expert Opin Ther Pat       Date:  2016-11-23       Impact factor: 6.674
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.